Moleculin Biotech Launches $9.1M Best-Efforts Offering at $2.19/Share with Warrants
MBRX is trading near its 52-week low of $1.01 (0.1% above the low) on elevated volume (2.9× avg).
Summary
Moleculin Biotech filed for a best-efforts offering to raise approximately $9.1 million at $2.19 per share with warrants, providing critical funding for its lead drug candidate Annamycin amid a going concern warning and near 52-week lows. The offering was later priced at $0.75 per share with three common warrants, with insiders buying 1,319,998 shares and 3,959,994 warrants, and net proceeds estimated at $8.5 million.
Updated with an SEC 424B5 filing · What changed
Updates
· SEC 424B5 — The offering is a best-efforts deal at $0.75 per share and three common warrants, with insiders buying 1,319,998 shares and 3,959,994 warrants. Net proceeds are estimated at $8.5 million.
Key Events · Financing and Capital Events · MBRX
-
Updated · · SEC 424B5
Best-Efforts Offering Priced at $0.75 with Three Warrants
Moleculin filed an S-1/A for a best-efforts public offering of up to 4,566,210 shares of common stock at an assumed combined price of $2.19 per share with accompanying Series I common warrants to purchase up to 13,698,630 shares, and pre-funded warrants to purchase up to 4,566,210 shares. The offering was later priced at $0.75 per share and three common warrants.
-
Updated · · SEC 424B5
Net Proceeds Revised to $8.5 Million
The offering is expected to generate approximately $9.1 million in net proceeds after placement agent fees and expenses, intended to advance Annamycin clinical development and for working capital. Net proceeds are later estimated at $8.5 million.
-
Updated · · SEC 424B5
Insiders Buy 1,319,998 Shares and 3,959,994 Warrants
One or more officers and directors have indicated non-binding interest in participating in the offering at the same terms as other purchasers. Insiders are buying 1,319,998 shares and 3,959,994 warrants.
-
Highly Dilutive Structure
If all shares and warrants are issued and exercised, the offering could more than double the current outstanding share count of 5.3 million, with up to 18.3 million additional shares underlying the warrants.
Analysis · MBRX · Life Sciences
Trading near its 52-week low of $1.01, Moleculin Biotech filed for a best-efforts offering of up to 4.57 million shares at an assumed price of $2.19 per share, together with Series I warrants to purchase up to 13.7 million shares. The estimated $9.1 million in net proceeds is critical runway for the company, which previously warned it needed $25 million and faces a going concern. The offering is highly dilutive—potentially more than doubling the outstanding share count if warrants are exercised—but provides essential capital to continue the pivotal MIRACLE trial for Annamycin. Insider participation signals some alignment, though the deep discount to recent prices and warrant overhang reflect the company's distressed position. The offering was later priced at $0.75 per share with three common warrants, with insiders buying 1,319,998 shares and 3,959,994 warrants, and net proceeds estimated at $8.5 million.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.01 to $18.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.